Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson’s disease

Overview of attention for article published in Proceedings of the National Academy of Sciences of the United States of America, June 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 9 news outlets
blogs: 6 blogs
twitter: 13 X users

patent: 10 patents
peer_reviews: 1 peer review site
facebook: 3 Facebook pages

Readers on

mendeley: 195 Mendeley

So far, Altmetric has seen 11 news stories from 9 outlets.

Parkinson Agent HL192 Successfully Completes Phase 1 First-In-Human Study

Neurology Live, 26 Nov 2024

HL192 met safety and tolerability endpoints in a phase 1 study, showing a favorable safety profile in healthy volunteers.

First human trial begun with Nurr1 activator HL192 in Parkinson’s disease

NewsBeezer, 22 Oct 2023

According to a recent announcement from HanAll Biopharma, Daewoong Pharmaceuticals and NurrOn Pharmaceuticals, first-in-human…

Début du premier essai chez l’homme sur l’activateur Nurr1 HL192 dans la maladie de Parkinson

Nouvelles du monde, 22 Oct 2023

Selon une annonce récente de HanAll Biopharma, Daewoong Pharmaceuticals et NurrOn Pharmaceuticals, le premier dosage chez l’homme…

First-In-Human Trial of Nurr1 Activator HL192 in Parkinson Disease Initiated

Neurology Live, 22 Oct 2023

In animal models, HL192 showed disease-modifying effects, as demonstrated through improvements in behavioral deficits.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 7 additional news stories.